Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma

References

• Institute NC: Surveillance epidemiology and end results program. SEER stat fact sheets on multiple myeloma; 2016 [cited 2016 Dec 13]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• List AF. Lenalidomide–the phoenix rises. N Engl J Med. 2007;357:2183–2186.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011 Mar 3:2011:394740.
   PubMedGoogle Scholar
• Catovsky D, Ikoku NB, Pitney WR, et al. Thromboembolic complications in myelomatosis. Br Med J. 1970 Aug 22;3:438–439.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991–4998.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY. Thrombosis in multiple myeloma. Hematol Am Soc Hematol Educ Program. 2010;2010:437–444.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Thrombosis is associated with inferior survival in multiple myeloma. Haematologica. 2012;97:1603–1607.
   PubMed Web of Science ®Google Scholar
• Libourel EJ, Sonneveld P, van der Holt B, et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010;116:22–26.
   PubMed Web of Science ®Google Scholar
• Yasin Z, Quick D, Thiagarajan P, et al. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol. 1999;62:99–102.
   PubMed Web of Science ®Google Scholar
• Isozumi Y, Arai R, Fujimoto K, et al. Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma. PLoS One. 2013;8:e64369.
   PubMed Web of Science ®Google Scholar
• Yang X, Brandenburg NA, Freeman J, et al. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009;29:161–171.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–656.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency: Lenalidomide: risk of thrombosis and thromboembolism; 2011 Feb. Available from: https://www.gov.uk/drug-safety-update/lenalidomide-risk-of-thrombosis-and-thromboembolism.
   Google Scholar
• Tannemaat MR, Vries EP, Molendijk WJ, et al. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma. Clin Neurol Neurosurg. 2011;113:488–489.
   PubMed Web of Science ®Google Scholar
• Rushworth GF, Leslie SJ, Forsyth P, et al. Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma. Ther Adv Drug Saf. 2012;3:115–122.
   PubMedGoogle Scholar
• Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164–170.
   PubMed Web of Science ®Google Scholar
• Menon SP, Rajkumar V, Lacy M, et al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer. 2008;112:1522–1528.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116:5838–5841.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006;108:403.
   PubMed Web of Science ®Google Scholar
• George J, Mahdi AJ, Sati HI. Risk of thrombotic events in patients with newly diagnosed (NDMM) and relapsed refractory multiple myeloma (RRMM) treated with lenalidomide based therapy: a single centre experience. Haematologica. 2015 Jun;100(Suppl. 1):742–743.
   Google Scholar
• Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69:56–63.
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746–755.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927–937.
   PubMed Web of Science ®Google Scholar
• Green D. Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism. Hematology Am Soc Hematol Educ Program. 2009;259–266. doi: 10.1182/asheducation-2009.1.259.
   PubMedGoogle Scholar
• Rosovsky R, Hong F, Tocco D, et al. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013;160:351–358.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080.
   PubMed Web of Science ®Google Scholar
• Rajkumar S, Greipp PR, Jacobus S, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Al-Ani F, Bermejo JM, Mateos MV, et al. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. Thromb Res. 2016;141:84–90.
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27:4865–4873.
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007 Aug 15;99:1232–1239.
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. Jama. 2008;300:2277–2285.
   PubMed Web of Science ®Google Scholar
• Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77:78–86.
   PubMed Web of Science ®Google Scholar
• Xu JQ, Murphy SL, Kochanek KD, et al. Mortality in the United States. In: 2015. NCHS data brief, no 267. Hyattsville (MD): National Center for Health Statistics; 2016.
   Google Scholar
• Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother. 2006;40:2101–2106.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Larocca A, Genuardi M, et al. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 2010;95:1144–1149.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Rouleau C, Echart C, et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009;15:1210–1221.
   PubMed Web of Science ®Google Scholar
• Martin MG, Vij R. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. Clin Lymphoma Myeloma. 2009;9:320–323.
   PubMedGoogle Scholar
• Alkindi S, Dennison D, Pathare A. Arterial and venous thrombotic complications with thalidomide in multiple myeloma. Arch Med Res. 2008 Feb;39:257–258.
   PubMed Web of Science ®Google Scholar
• Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis. 2008;25:224–226.
   PubMed Web of Science ®Google Scholar
• Leleu X, Rodon P, Hulin C, et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost. 2013;110:844–851.
   PubMed Web of Science ®Google Scholar
• Van Marion AM, Auwerda JJ, Lisman T, et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res. 2008;32:1078–1084.
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568–1574.
   PubMed Web of Science ®Google Scholar
• Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933–939.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Pomalidomide: Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER); 2016 Jun. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm446484.htm
   Google Scholar